Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Exelixis Inc.
Sponsor

Exelixis Inc.

United States 1851 Harbor Bay Parkway, 94502-3010, United States

About the sponsor

Research activity centers on advanced clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, and broader metastatic renal cell carcinoma, with attention to treatment settings spanning first-line through later-line care. The portfolio also includes bladder cancer and urothelial carcinoma, including both ICI-naïve and ICI-experienced disease.

  • Advanced clear cell renal cell carcinoma
  • Non-clear cell renal cell carcinoma
  • Urothelial carcinoma
  • Bladder cancer

These studies reflect sustained interest in kidney and urinary tract cancers, with emphasis on difficult-to-treat metastatic disease.

About Specializations

Exelixis Inc. runs clinical trials in conditions such as Hormone-refractory prostate cancer, Pancreatic neuroendocrine tumour, Neoplasm malignant, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

10 clinical trials

Pancreatic neuroendocrine tumour

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Neoplasm malignant+7

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Exelixis Inc.

Renal cell carcinoma

Not yet recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Squamous cell carcinoma of head and neck

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Medullary thyroid cancer

Not recruiting
Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Colorectal cancer metastatic

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Hormone-refractory prostate cancer

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Exelixis Inc.

Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Renal cancer metastatic

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Thyroid cancer

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.